Guidelines for endometrial cancer management: finding order amid the uncertainties (English)
- New search for: Eifel, P. J.
- New search for: Eifel, P. J.
In:
ANNALS OF ONCOLOGY
;
27
, 2
;
212-213
;
2016
-
ISSN:
- Article (Journal) / Print
-
Title:Guidelines for endometrial cancer management: finding order amid the uncertainties
-
Contributors:Eifel, P. J. ( author )
-
Published in:ANNALS OF ONCOLOGY ; 27, 2 ; 212-213
-
Publisher:
- New search for: OXFORD UNIVERSITY PRESS
-
Publication date:2016-01-01
-
Size:2 pages
-
ISSN:
-
Type of media:Article (Journal)
-
Type of material:Print
-
Language:English
- New search for: 616.992
- Further information on Dewey Decimal Classification
-
Classification:
DDC: 616.992 -
Source:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Table of contents – Volume 27, Issue 2
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 211
-
Environmental emissions, public health and lung cancer riskSwanton, C. / Boffetta, P. / Peston, R. / Soria, J. C. et al. | 2016
- 212
-
Guidelines for endometrial cancer management: finding order amid the uncertaintiesEifel, P. J. et al. | 2016
- 214
-
Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodiesPostel-Vinay, S. / Aspeslagh, S. / Lanoy, E. / Robert, C. / Soria, J. C. / Marabelle, A. et al. | 2016
- 225
-
Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancerDonnem, T. / Kilvaer, T. K. / Andersen, S. / Richardsen, E. / Paulsen, E. E. / Hald, S. M. / Al-Saad, S. / Brustugun, O. T. / Helland, A. / Lund-Iversen, M. et al. | 2016
- 233
-
Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeuticsDimopoulos, M. A. / Kastritis, E. / Ghobrial, I. M. et al. | 2016
- 240
-
Beyond the exome: the role of non-coding somatic mutations in cancerPiraino, S. W. / Furney, S. J. et al. | 2016
- 249
-
Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancerPruneri, G. / Vingiani, A. / Bagnardi, V. / Rotmensz, N. / De Rose, A. / Palazzo, A. / Colleoni, A. M. / Goldhirsch, A. / Viale, G. et al. | 2016
- 256
-
In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer ConsortiumLobbezoo, D. J. / van Kampen, R. J. / Voogd, A. C. / Dercksen, M. W. / van den Berkmortel, F. / Smilde, T. J. / van de Wouw, A. J. / Peters, F. P. / van Riel, J. M. / Peters, N. A. et al. | 2016
- 257
-
Can ovarian suppression with gonadotropin-releasing hormone analogs (GnRHa) preserve fertility in cancer patients?Rodriguez-Wallberg, K. / Turan, V. / Munster, P. / Oktay, K. et al. | 2016
- 262
-
Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer†Mitsuhashi, A. / Sato, Y. / Kiyokawa, T. / Koshizaka, M. / Hanaoka, H. / Shozu, M. et al. | 2016
- 267
-
Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIVLévi, F. A. / Boige, V. / Hebbar, M. / Smith, D. / Lepère, C. / Focan, C. / Karaboué, A. / Guimbaud, R. / Carvalho, C. / Tumolo, S. et al. | 2016
- 274
-
A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinomaRosati, G. / Ambrosini, G. / Barni, S. / Andreoni, B. / Corradini, G. / Luchena, G. / Daniele, B. / Gaion, F. / Oliverio, G. / Duro, M. et al. | 2016
- 281
-
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohortMazières, J. / Barlesi, F. / Filleron, T. / Besse, B. / Monnet, I. / Beau-Faller, M. / Peters, S. / Dansin, E. / Früh, M. / Pless, M. et al. | 2016
- 286
-
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAILGraff, J. N. / Baciarello, G. / Armstrong, A. J. / Higano, C. S. / Iversen, P. / Flaig, T. W. / Forer, D. / Parli, T. / Phung, D. / Tombal, B. et al. | 2016
- 294
-
Pre-treatment lymphocytopaenia is an adverse prognostic biomarker in muscle-invasive and advanced bladder cancer†Joseph, N. / Dovedi, S. J. / Thompson, C. / Lyons, J. / Kennedy, J. / Elliott, T. / West, C. M. / Choudhury, A. et al. | 2016
- 300
-
Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumorsCierna, Z. / Mego, M. / Miskovska, V. / Machalekova, K. / Chovanec, M. / Svetlovska, D. / Hainova, K. / Rejlekova, K. / Macak, D. / Spanik, S. et al. | 2016
- 306
-
Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomesLaurent, C. / Delas, A. / Gaulard, P. / Haioun, C. / Moreau, A. / Xerri, L. / Traverse-Glehen, A. / Rousset, T. / Quintin-Roue, I. / Petrella, T. et al. | 2016
- 314
-
Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center studyLassalle, A. / Thomaré, P. / Fronteau, C. / Mahé, B. / Jubé, C. / Blin, N. / Voldoire, M. / Dubruille, V. / Tessoulin, B. / Touzeau, C. et al. | 2016
- 318
-
Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumorsWong, S. J. / Karrison, T. / Hayes, D. N. / Kies, M. S. / Cullen, K. J. / Tanvetyanon, T. / Argiris, A. / Takebe, N. / Lim, D. / Saba, N. F. et al. | 2016
- 324
-
The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06)Strasser, F. / Blum, D. / von Moos, R. / Cathomas, R. / Ribi, K. / Aebi, S. / Betticher, D. / Hayoz, S. / Klingbiel, D. / Brauchli, P. et al. | 2016
- 332
-
Next-generation sequencing of the basal cell carcinoma miRNome and a description of novel microRNA candidates under neoadjuvant vismodegib therapy: an integrative molecular and surgical case studySand, M. / Bechara, F. G. / Gambichler, T. / Sand, D. / Friedländer, M. R. / Bromba, M. / Schnabel, R. / Hessam, S. et al. | 2016
- 339
-
Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance)†Yoon, H. H. / Foster, N. R. / Meyers, J. P. / Steen, P. D. / Visscher, D. W. / Pillai, R. / Prow, D. M. / Reynolds, C. M. / Marchello, B. T. / Mowat, R. B. et al. | 2016
- 344
-
Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?Postel-Vinay, S. / Boursin, Y. / Massard, C. / Hollebecque, A. / Ileana, E. / Chiron, M. / Jung, J. / Lee, J. S. / Balogh, Z. / Adam, J. et al. | 2016
- 353
-
Access to innovative oncology medicines in EuropeBergmann, L. / Enzmann, H. / Thirstrup, S. / Schweim, J. K. / Widera, I. / Zwierzina, H. et al. | 2016
- 358
-
Prevalence of rare EGFR gene mutations in nonsmall-cell lung cancer: a multicenter study on 3856 Polish Caucasian patientsKrawczyk, P. / Reszka, K. / Ramlau, R. / Powrózek, T. / Pankowski, J. / Wojas-Krawczyk, K. / Kalinka-Warzocha, E. / Szczęsna, A. / Nicoś, M. / Jarosz, B. et al. | 2016
- 359
-
Reply to the letter to the editor ‘Prevalence of rare EGFR mutations in non-small cell lung cancer: a multicenter study on 3856 Polish Caucasian patients’ by Krawczyk et al.Beau-Faller, M. / Cadranel, J. et al. | 2016
- 360
-
KRT81 miR-SNP rs3660 is associated with risk and survival of NSCLCRobles, A. I. / Ryan, B. M. et al. | 2016
- 361
-
Reply to the letter to the editor ‘KRT81 miR-SNP rs3660 is associated with risk and survival of NSCLC’ by Robles et al.Lee, S. Y. / Choi, J. E. / Park, J. Y. et al. | 2016
- 363
-
More colors to the paletteBracarda, S. et al. | 2016
- 363
-
Reply to ‘Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance’ by Funck-Brentano et al.Goldwirt, L. / Chami, I. / Feugeas, J. P. / Pages, C. / Brunet-Possenti, F. / Allayous, C. / Baroudjian, B. / Madelaine, I. / Sauvageon, H. / Mourah, S. et al. | 2016
- 364
-
Reply to the letter to the editor ‘Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumor response and tolerance’ by Funck-Brentano et al.Funck-Brentano, E. / Alvarez, J. C. / Longvert, C. / Abe, E. / Beauchet, A. / Saiag, P. / Funck-Brentano, C. et al. | 2016
- 366
-
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysisBracarda, S. / Iacovelli, R. / Boni, L. / Rizzo, M. / Derosa, L. / Rossi, M. / Galli, L. / Procopio, G. / Sisani, M. / Longo, F. et al. | 2016